{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T21:47:29Z","timestamp":1778795249348,"version":"3.51.4"},"reference-count":27,"publisher":"Wiley","issue":"2","license":[{"start":{"date-parts":[[2011,9,6]],"date-time":"2011-09-06T00:00:00Z","timestamp":1315267200000},"content-version":"vor","delay-in-days":4784,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["American J Rep Immunol"],"published-print":{"date-parts":[[1998,8]]},"abstract":"<jats:p>PROBLEM: The effect of mini\u2010dose heparin\/aspirin (H\/A) alone vs. combined intravenous immunoglobulin G (IVIg) and H\/A on <jats:italic>in vitro<\/jats:italic> fertilization (IVF) birthrates in women who test seropositive for antiphospholipid antibodies (APA+) was evaluated, as was the question of whether outcome is influenced by the gammaglobulin isotype(s) or the phospholipid (PL) epitope(s) to which the APAs are directed.<\/jats:p><jats:p><jats:bold>METHOD OF STUDY<\/jats:bold>: A case\u2010control study was conducted in three phases, spanning a 4\u2010year period, in a multicenter clinical research environment. Six hundred eighty\u2010seven APA+ women, who were younger than 40 years and who each, completed up to three consecutive IVF\/embryo transfer cycles within a 12\u2010month period, were given either H\/A alone or H\/A in combination with IVIg. Birthrates relative to the type of immunotherapy (i.e., H\/A alone and H\/A with IVIg) and APA profile were the main outcome measurements.<\/jats:p><jats:p>RESULTS: In phase I, 687 women who tested APA+ to one or more PL epitopes underwent two or fewer IVF attempts for a total of 1050 IVF cycles. Four hundred seventy\u2010seven (46%) births occurred in 923 IVF cycles in which H\/A alone was administered. Twenty\u2010two (17%) births occurred after 127 IVF cycles in which H\/A was not administered. In phase II, 322 of 687 women tested positive for a single APA subtype. These subjects underwent up to two consecutive IVF attempts for a total of 521 IVF cycles while receiving H\/A alone. The birthrate was significantly lower for women whose APAs were directed toward phosphatidylethanolamine (PE) or phosphatidylserine (PS) involving IgG or IgM isotypes than for women who had any other APA (17% vs. 43%). In phase III, 121 women who did not achieve live births after two consecutive IVF attempts in which H\/A alone was administered received IVIg in combination with H\/A during their third consecutive IVF cycle. The birth rate was 41% after these IVF cycles when anti\u2010PS or anti\u2010PE involving IgG or IgM isotypes were present, as compared with 17% when H\/A alone was administered. The IVF outcome did not improve when IVIg was administered in association with any other single APA.<\/jats:p><jats:p>CONCLUSIONS: The treatment of APA+ women with H\/A alone improves IVF birthrates. This benefit is selective in that it does not apply in cases in which IgG\u2010 or IgM\u2010related APAs are directed against PE or PS. In such cases, the addition of IVIg significantly improves the outcome.<\/jats:p>","DOI":"10.1111\/j.1600-0897.1998.tb00394.x","type":"journal-article","created":{"date-parts":[[2011,9,6]],"date-time":"2011-09-06T11:45:58Z","timestamp":1315309558000},"page":"74-82","source":"Crossref","is-referenced-by-count":81,"title":["The Selective Use of Heparin\/Aspirin Therapy, Alone or in Combination with Intravenous Immunoglobulin G, in the Management of Antiphospholipid Antibody\u2010Positive Women Undergoing <i>In Vitro<\/i> Fertilization"],"prefix":"10.1111","volume":"40","author":[{"given":"Geoffrey","family":"Sher","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"William","family":"Matzner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"Feinman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ghanima","family":"Maassarani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christo","family":"Zouves","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Penny","family":"Chong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wendell","family":"Ching","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2011,9,6]]},"reference":[{"key":"e_1_2_1_2_2","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1016\/S0015-0282(16)55910-X","article-title":"Assisted reproductive technology in the United States and Canada: 1991 results from the Society of Assisted Reproductive Technology generated from the American Fertility Society Registry","volume":"59","author":"Society of Assisted Reproductive Technology","year":"1993","journal-title":"Fertil Steril"},{"key":"e_1_2_1_3_2","first-page":"645","article-title":"Immunologic aspects of recurrent abortion and fetal death","volume":"70","author":"Scott JR","year":"1987","journal-title":"Obstet Gynecol"},{"key":"e_1_2_1_4_2","doi-asserted-by":"publisher","DOI":"10.1002\/art.1780341005"},{"key":"e_1_2_1_5_2","doi-asserted-by":"publisher","DOI":"10.1097\/00006254-199406000-00026"},{"key":"e_1_2_1_6_2","first-page":"433","article-title":"Antiphospholipid antibodies and pregnancy loss","volume":"33","author":"Rote NS","year":"1995","journal-title":"Am J Reprod Immunol"},{"key":"e_1_2_1_7_2","first-page":"441","volume-title":"The Human Placenta","author":"Sargent IL","year":"1993"},{"key":"e_1_2_1_8_2","doi-asserted-by":"publisher","DOI":"10.1093\/oxfordjournals.humrep.a138437"},{"key":"e_1_2_1_9_2","doi-asserted-by":"publisher","DOI":"10.1093\/oxfordjournals.humrep.a135745"},{"key":"e_1_2_1_10_2","first-page":"286","article-title":"Treatment of autoimmune\u2010associated recurrent pregnancy loss with ASA and heparin: A case series","volume":"32","author":"Stephenson MD","year":"1995","journal-title":"Am J Reprod Immunol"},{"key":"e_1_2_1_11_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0897.1996.tb00032.x"},{"key":"e_1_2_1_12_2","doi-asserted-by":"publisher","DOI":"10.1093\/oxfordjournals.humrep.a138435"},{"key":"e_1_2_1_13_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199201093260206"},{"key":"e_1_2_1_14_2","first-page":"27","article-title":"Characterization of antiphospholipid antibodies in women with recurrent spontaneous abortions","volume":"39","author":"Matzner W.","year":"1994","journal-title":"J Reprod Med"},{"key":"e_1_2_1_15_2","doi-asserted-by":"publisher","DOI":"10.1093\/oxfordjournals.humrep.a137312"},{"key":"e_1_2_1_16_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0897.1996.tb00499.x"},{"key":"e_1_2_1_17_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0897.1992.tb00753.x"},{"key":"e_1_2_1_18_2","first-page":"436","article-title":"Influence of prostaglandins and platelet activating factor on implantation","volume":"6","author":"Weiden RMF","year":"1992","journal-title":"Hum Reprod"},{"key":"e_1_2_1_19_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0897.1996.tb00494.x"},{"key":"e_1_2_1_20_2","doi-asserted-by":"publisher","DOI":"10.1016\/0165-0378(94)00918-W"},{"key":"e_1_2_1_21_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0897.1996.tb00496.x"},{"key":"e_1_2_1_22_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1749-6632.1994.tb21751.x"},{"key":"e_1_2_1_23_2","unstructured":"KleinsteinJ. KhanagaO. GipsH. KunzelW.:Intravenous immunoglobulins increase clinical pregnancy rates in an IVF program.Proceedings of the 41st annual meeting of the Society for Gynecological Investigation 1994 abstract P108."},{"key":"e_1_2_1_24_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0897.1996.tb00041.x"},{"key":"e_1_2_1_25_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0897.1996.tb00141.x"},{"key":"e_1_2_1_26_2","doi-asserted-by":"publisher","DOI":"10.1016\/0014-5793(81)80554-6"},{"key":"e_1_2_1_27_2","doi-asserted-by":"publisher","DOI":"10.1016\/0005-2736(83)90442-X"},{"key":"e_1_2_1_28_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0015-0282(97)81443-4"}],"container-title":["American Journal of Reproductive Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1600-0897.1998.tb00394.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1600-0897.1998.tb00394.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,28]],"date-time":"2023-10-28T03:43:45Z","timestamp":1698464625000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1600-0897.1998.tb00394.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1998,8]]},"references-count":27,"journal-issue":{"issue":"2","published-print":{"date-parts":[[1998,8]]}},"alternative-id":["10.1111\/j.1600-0897.1998.tb00394.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1600-0897.1998.tb00394.x","archive":["Portico"],"relation":{},"ISSN":["1046-7408","1600-0897"],"issn-type":[{"value":"1046-7408","type":"print"},{"value":"1600-0897","type":"electronic"}],"subject":[],"published":{"date-parts":[[1998,8]]}}}